03/03
Headlines

AGEN

Biotech Bearish Stocks: Zalicus Inc (NASDAQ:ZLCS), Stemline Therapeutics Inc (NASDAQ:STML), Agenus Inc (NASDAQ:AGEN), Arrowhead Research Corp (NASDAQ:ARWR), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Kevin Long03 mins

Zalicus Inc (NASDAQ:ZLCS) on June 18 announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in…

Read More

Biotech Early Movers: OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI), Agenus Inc(NASDAQ:AGEN), Athersys, Inc.(NASDAQ:ATHX)

Colin Pettis03 mins

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) shares plunged more than 48% pre-market after the company said results from its Phase 3 SYNERGY trial to add custirsen to standard first-line treatment of docetaxel/prednisone in men with metastatic prostate cancer failed to meet primary endpoints. The stock which was halted from trading ahead of the news, recently changed hands…

Read More

Biotech Volatile Stocks: NewLink Genetics Corp (NASDAQ:NLNK), Alnylam Pharmaceuticals (NASDAQ:ALNY), Kindred Biosciences (NASDAQ:KIN), Agenus (NASDAQ:AGEN)

John Bellich02 mins

NewLink Genetics Corp (NASDAQ:NLNK)’s algenpantucel-L is expected to garner the highest sales and will be launched in both resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck’s TH-302 and Merrimack Pharmaceuticals’ MM-398,” director says. NewLink Genetics Corp (NASDAQ:NLNK) stock performance was -9.03% in last session and finished the…

Read More